Viromed Medical AG Restructures Management Board to Drive Next Growth Phase

Viromed Medical AG appoints Christian Strauch to its Management Board as founder Uwe Perbandt resigns, signaling a strategic shift to capitalize on the company's cold plasma technology market readiness.

Chicago Metrowire Staff
••Healthcare
Viromed Medical AG Restructures Management Board to Drive Next Growth Phase

Viromed Medical AG has announced a significant change to its Management Board, appointing Christian Strauch effective November 16, 2026, for a term lasting until October 31, 2029. At the same time, founder and CEO Uwe Perbandt has resigned from his position for personal reasons, effective December 31, 2026. The move, reported via NEWMEDIAWIRE, marks a pivotal moment for the company as it transitions from its entrepreneurial roots to a new phase of growth.

The restructuring is more than a routine leadership change; it reflects Viromed's strategic intent to leverage its recently achieved market readiness in cold plasma technology. Dr. Thomas Gutschlag, Chairman of the Supervisory Board, emphasized that the change occurs by mutual agreement and praised Perbandt's role in building Viromed into an internationally leading enterprise in cold plasma technology. Gutschlag noted that the company now stands at the threshold of an exciting next growth phase, and he expressed confidence that Strauch's sales expertise makes him the ideal candidate to help shape this phase successfully.

Perbandt's departure is amicable, with the founder stating that he built Viromed with passion and a dedicated team, and that he is proud of what they achieved together. He highlighted the importance of cold plasma technology in helping people and saving lives, and expressed confidence in handing over responsibility to Strauch, whom he described as a highly experienced successor and his preferred candidate. This smooth transition is likely to reassure investors and stakeholders about the continuity of Viromed's mission and operations.

Christian Strauch brings over twenty years of experience in building and scaling healthcare companies. As Managing Director of pharmedix GmbH, a Viromed subsidiary, he has already demonstrated his ability to reposition businesses for growth. His track record includes founding and scaling the mail-order pharmacy apo-rot to 450 employees and annual revenue of up to EUR 100 million, overseeing its sale to the Zur Rose Group, and leading integration efforts at DocMorris subsidiaries. He also founded two pharmaceutical wholesalers and has been building the Vameda Group since 2020. This extensive background in sales and operational scaling is precisely what Viromed needs as it seeks to expand the commercial reach of its cold plasma technology.

The implications of this announcement extend beyond the boardroom. Viromed Medical AG, listed on the stock exchange since October 2022, has positioned itself as a pioneer in medical cold plasma technology, with a broad customer base in the DACH region and beyond. The company's goal is to further advance the use of cold plasma in medicine and realize its growth potential. Strauch's appointment signals a stronger focus on sales and market penetration, which could accelerate revenue growth and strengthen Viromed's competitive position. Investors and industry observers will be watching closely to see how the new management team capitalizes on the technology's market readiness.

For more information, the original release is available on www.newmediawire.com.

Blockchain Registration

QR Code for Blockchain Registration